Can ‘Cryptic Peptides’ Peg People with TDP-43 Pathology?
Mis-splicing events produce novel proteins that can be detected in the cerebrospinal fluid of ALS/FTD patients before their symptoms start.
6448 RESULTS
Sort By:
Mis-splicing events produce novel proteins that can be detected in the cerebrospinal fluid of ALS/FTD patients before their symptoms start.
Using live imaging, electron microscopy, and gene expression studies, two groups show that a purported fourth membrane is instead the inner layer of the arachnoid mater.
First look at substrate interactions reveals similarities but some surprises.
Lecanemab will soon have maintenance dosing and subcutaneous formulations available; FDA advisory committee will consider donanemab June 10.
The widely used psychiatric drug lithium, and other agents that inhibit glycogen synthase kinase-3 (GSK3), have been mentioned as possible Alzheimer's disease therapies for some time, primarily because GSK3 is one of several kinases known to phosphorylate tau...
A mixed bag of epidemiologic studies alternatively hold up and knock down the promise that...
As the first of a suite of PET β amyloid imaging agents stands poised to receive a ruling from the FDA, seven scientists are questioning the validity of this technology...
A paper out today in Cell proposes a novel role for presenilins in calcium signaling...
Of all clinical trials reported at the ICAD, one targeting the protein tau was the <em>therapy du jour</em>...
In the future, could Alzheimer disease treatments come as an ointment, or a skin patch?...
After a tough year, during which believers in immunotherapy for Alzheimer’s disease have had to fend off vociferous criticism, the news now appears to pick up...
On Saturday, 27 October, in Los Angeles, an unusual conference marked a paradigm shift in the Alzheimer disease movement...
Flurizan has floundered in an 18-month Phase 3 clinical trial in patients with mild Alzheimer disease...
Alzheimer's disease researchers expressed sadness this week at the sudden death of Larry Sparks...
A new study finds that the cancer drug imatinib does not lower Aβ in humans, casting doubt on a previously described relationship between imatinib, γ-secretase activating protein (GSAP), and Aβ.